JP2021155436A5 - - Google Patents

Download PDF

Info

Publication number
JP2021155436A5
JP2021155436A5 JP2021103893A JP2021103893A JP2021155436A5 JP 2021155436 A5 JP2021155436 A5 JP 2021155436A5 JP 2021103893 A JP2021103893 A JP 2021103893A JP 2021103893 A JP2021103893 A JP 2021103893A JP 2021155436 A5 JP2021155436 A5 JP 2021155436A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cyclodextrin
derivative
hydroxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021103893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021155436A (ja
Filing date
Publication date
Priority claimed from JP2018150978A external-priority patent/JP2018203747A/ja
Application filed filed Critical
Publication of JP2021155436A publication Critical patent/JP2021155436A/ja
Publication of JP2021155436A5 publication Critical patent/JP2021155436A5/ja
Priority to JP2023146755A priority Critical patent/JP2023178518A/ja
Pending legal-status Critical Current

Links

JP2021103893A 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法 Pending JP2021155436A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023146755A JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
US61/624,087 2012-04-13
JP2018150978A JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018150978A Division JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023146755A Division JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Publications (2)

Publication Number Publication Date
JP2021155436A JP2021155436A (ja) 2021-10-07
JP2021155436A5 true JP2021155436A5 (cg-RX-API-DMAC7.html) 2022-02-21

Family

ID=49328287

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法
JP2018150978A Pending JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法
JP2018150978A Pending JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Country Status (8)

Country Link
US (4) US10195227B2 (cg-RX-API-DMAC7.html)
EP (2) EP4299121A3 (cg-RX-API-DMAC7.html)
JP (4) JP6491089B2 (cg-RX-API-DMAC7.html)
CN (2) CN111419870A (cg-RX-API-DMAC7.html)
CA (1) CA2870316C (cg-RX-API-DMAC7.html)
ES (1) ES2959119T3 (cg-RX-API-DMAC7.html)
MX (2) MX371073B (cg-RX-API-DMAC7.html)
WO (1) WO2013155485A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin
CN105611909B (zh) 2013-03-12 2020-09-15 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Glp−1分泌促進剤
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
CN109982718A (zh) * 2016-09-19 2019-07-05 阿托恩波罗斯生命科学 基于环糊精的聚合物、方法、组合物及其应用
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
EP3873604B1 (en) 2018-10-29 2024-08-21 Cyclo Therapeutics, Inc. Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
AU2020204925B2 (en) 2019-01-03 2025-11-20 Cyclarity Therapeutics, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
CA3158077A1 (en) * 2019-11-11 2021-05-20 Atsuo Ochi Method and a kit to reprogram somatic cells
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
CA3189915A1 (en) * 2020-08-27 2022-03-03 Diana KERWIN Methods for the treatment of cardiovascular disease with cyclodextrins
AU2021331485A1 (en) * 2020-08-27 2023-03-23 Beren Therapeutics P.B.C. Methods for the prevention of cholesterol crystal embolization with cyclodextrins
US20230330133A1 (en) * 2020-08-27 2023-10-19 Beren Therapeutics P.B.C. Methods for the treatment of cholesterol crystal embolization with cyclodextrins
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
EP4294403A4 (en) * 2021-02-18 2024-12-11 Beren Therapeutics P.B.C. METHODS OF TREATMENT OF HETEROZYGOUS AND HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH CYCLODEXTRINS
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
CN116322710A (zh) * 2021-09-01 2023-06-23 株式会社雷纳图斯 包括γ-环糊精聚合物的药物组合物以及其用途
JP2025506676A (ja) 2022-02-18 2025-03-13 ベレン セラピューティクス ピー.ビー.シー. ヒドロキシプロピル-ベータ-シクロデキストリンの組成物及びその精製方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) * 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
US6756504B2 (en) 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
BRPI0309572B1 (pt) * 2002-08-19 2017-02-21 Art Jen Complexus Inc composições compreendendo complexante de gordura da dieta e processos para seu uso
JP2004323443A (ja) * 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
US20060148721A1 (en) * 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
EP1845787B1 (en) 2005-01-27 2015-04-15 Erimos Pharmaceuticals LLC Formulations for injection of catecholic butanes, including ndga compounds, into animals
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) * 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
NZ575394A (en) 2006-10-20 2012-01-12 Icos Corp Compositions of chk1 inhibitors and cyclodextrin
EP1920785A1 (en) * 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
CN102438614A (zh) 2008-10-10 2012-05-02 利默里克生物制药公司 用于治疗的吡喃酮类似物
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
WO2010054167A2 (en) 2008-11-06 2010-05-14 University Of Miami Limited proteolysis of cd2ap and progression of renal disease
US20110314423A1 (en) 2009-03-12 2011-12-22 Panasonic Corporation Image display device and image display method
JP5847721B2 (ja) * 2009-10-08 2016-01-27 ソン、ホ、バイオメッド、カンパニー、リミテッドSong Ho Biomed Co., Ltd 高水溶性2−ヒドロキシプロピル−ベータシクロデキストリンを有効成分として含有する、肥満疾患の予防および治療用組成物
US20120251527A1 (en) 2009-11-06 2012-10-04 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
US9044451B2 (en) 2010-07-19 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
WO2012054321A2 (en) * 2010-10-19 2012-04-26 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin

Similar Documents

Publication Publication Date Title
Todd et al. Ramipril: a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders
CA2943373C (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
JP2015512949A5 (cg-RX-API-DMAC7.html)
US20140243282A1 (en) Methods and compositions for designing novel conjugate therapeutics
MXPA06014023A (es) Terapias combinadas que utilizan inhibidores de benzamida del receptor p2x7.
US20230114153A1 (en) Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
JP2023539614A (ja) アンジオテンシンiiに関連する疾患の治療に使用するための新規化合物
JP2002501039A (ja) Vla−4アンタゴニスト
EP1248614A2 (en) Non-peptide inhibition of t-lymphocyte activation and therapies related thereto
EP4073043B1 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
US20150182503A1 (en) Mineralocorticoid receptor antagonists
Bodor et al. Retrometabolic drug design: principles and recent developments
JP2023505587A (ja) 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用
JPH0640915A (ja) 自己免疫疾患処置のための医薬組成物
EP1032386B1 (en) Use of oxazolidinone derivatives for treating arthritis
CN103827111B (zh) N-杂环取代酰胺衍生物
JP2026501412A (ja) 眼粘膜類天疱瘡及び/又は口腔粘膜類天疱瘡の治療に使用するためのcxcl8阻害薬
WO1998051313A1 (fr) Remedes contre les yeux secs
HK40081690A (en) Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
HK40081690B (en) Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
EP4678171A1 (en) Systemically-administered cxcl8 inhibitors for use in the prevention or treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
US10174054B2 (en) Compounds and methods for the treatment of Alzheimer's disease and/or cerebral amyloid angiopathy
HK40076778B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HK1261676B (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
HK1261676A1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders